Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. Pfizer has denied access to Paxlovid for an independent RCT
[Ledford ] .
[Hoertel ] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
0
0.5
1
1.5+
All studies
39%
22
40,041
Improvement, Studies, Patients
Relative Risk
Mortality
63%
11
24,101
Ventilation
30%
3
4,954
ICU admission
31%
3
4,319
Hospitalization
47%
10
22,956
Progression
41%
2
4,040
Recovery
5%
2
142
Cases
37%
1
1,971
Viral clearance
17%
7
2,491
RCTs
69%
3
5,201
RCT mortality
90%
2
3,230
Peer-reviewed
41%
13
6,705
Prophylaxis
37%
1
1,971
Early
44%
21
38,162
Late
32%
1
307
Paxlovid for COVID-19
c19 early.org/pl Feb 2023
Favors paxlovid
Favors control
after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW)
19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+
79%
0.21 [0.05-0.82]
death
Arbel 40-64
-32%
1.32 [0.16-10.8]
death
Najjar-Debbiny
46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson
71%
0.29 [0.12-0.71]
death
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES)
79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu
12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM)
95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong
15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhou (PSM)
73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM)
66%
0.34 [0.22-0.52]
death
Schwartz (PSW)
50%
0.50 [0.41-0.61]
death
Pandit
1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Bajema (PSM)
58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW)
-4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans
41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.11, I2 = 85.4%, p < 0.0001
Early treatment
44%
0.56 [0.47-0.68]
45/13,783
301.6/24,379
44% improvement
Li
32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment
32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement
Pfizer (DB RCT)
37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis
37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement
All studies
39%
0.61 [0.53-0.72]
85/14,852
431.6/25,588
39% improvement
Paxlovid COVID-19 studies
c19 early.org/pl Feb 2023
Tau2 = 0.07, I2 = 80.4%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW)
19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+
79%
0.21 [0.05-0.82]
death
Arbel 40-64
-32%
1.32 [0.16-10.8]
death
Najjar-Debbiny
46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson
71%
0.29 [0.12-0.71]
death
Li (ES)
79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu
12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM)
95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Zhong
15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhou (PSM)
73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM)
66%
0.34 [0.22-0.52]
death
Schwartz (PSW)
50%
0.50 [0.41-0.61]
death
Pandit
1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Bajema (PSM)
58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW)
-4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans
41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.18, I2 = 86.2%, p < 0.0001
Early treatment
49%
0.51 [0.40-0.65]
45/13,749
301.6/24,151
49% improvement
Li
32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment
32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement
Pfizer (DB RCT)
37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis
37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement
All studies
43%
0.57 [0.47-0.70]
85/14,818
431.6/25,360
43% improvement
Paxlovid COVID-19 studies after exclusions
c19 early.org/pl Feb 2023
Tau2 = 0.12, I2 = 81.5%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
66%
0.34 [0.23-0.50]
890 (n)
890 (n)
Arbel 65+
79%
0.21 [0.05-0.82]
Arbel 40-64
-32%
1.32 [0.16-10.8]
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
0/576
1/569
Dryden-Peterson
71%
0.29 [0.12-0.71]
Ganatra (PSM)
95%
0.05 [0.00-0.81]
0/1,130
10/1,130
Zhou (PSM)
73%
0.27 [0.13-0.58]
7/2,808
100/10,849
Wong (PSM)
66%
0.34 [0.22-0.52]
Schwartz (PSW)
50%
0.50 [0.41-0.61]
Bajema (PSM)
58%
0.42 [0.26-0.67]
20/1,587
48.6/1,587
Tau2 = 0.04, I2 = 33.4%, p < 0.0001
Early treatment
63%
0.37 [0.29-0.48]
27/8,030
171.6/16,071
63% improvement
All studies
63%
0.37 [0.29-0.48]
27/8,030
171.6/16,071
63% improvement
11 paxlovid COVID-19 mortality results
c19 early.org/pl Feb 2023
Tau2 = 0.04, I2 = 33.4%, p < 0.0001
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM)
3%
0.97 [0.31-3.03]
890 (n)
890 (n)
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
38%
0.62 [0.23-1.72]
Bajema (PSM)
48%
0.52 [0.12-2.16]
3/1,587
5.8/1,587
Tau2 = 0.00, I2 = 0.0%, p = 0.3
Early treatment
30%
0.70 [0.36-1.36]
3/2,477
5.8/2,477
30% improvement
All studies
30%
0.70 [0.36-1.36]
3/2,477
5.8/2,477
30% improvement
3 paxlovid COVID-19 mechanical ventilation results
c19 early.org/pl Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.3
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Pfizer (DB RCT)
86%
0.14 [0.01-2.75]
0/576
3/569
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
-58%
1.58 [0.95-2.63]
Bajema (PSM)
56%
0.44 [0.21-0.92]
10/1,587
22.8/1,587
Tau2 = 0.74, I2 = 78.9%, p = 0.55
Early treatment
31%
0.69 [0.21-2.27]
10/2,163
25.8/2,156
31% improvement
All studies
31%
0.69 [0.21-2.27]
10/2,163
25.8/2,156
31% improvement
3 paxlovid COVID-19 ICU results
c19 early.org/pl Feb 2023
Tau2 = 0.74, I2 = 78.9%, p = 0.55
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
88%
0.12 [0.06-0.26]
hosp.
8/1,039
65/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
4%
0.96 [0.88-1.04]
hosp. time
890 (n)
890 (n)
Yip (PSW)
21%
0.79 [0.65-0.95]
hosp.
Arbel 65+
73%
0.27 [0.15-0.49]
hosp.
Arbel 40-64
26%
0.74 [0.35-1.58]
hosp.
Dryden-Peterson
40%
0.60 [0.44-0.81]
hosp.
Ganatra (PSM)
56%
0.44 [0.21-0.91]
hosp.
10/1,130
23/1,130
Zhou (PSM)
84%
0.16 [0.11-0.22]
hosp.
34/2,808
752/10,849
Wong (PSM)
24%
0.76 [0.67-0.86]
hosp.
Bajema (PSM)
7%
0.93 [0.74-1.16]
hosp.
180/1,587
194.2/1,587
Tau2 = 0.16, I2 = 93.5%, p < 0.0001
Early treatment
47%
0.53 [0.39-0.71]
232/7,454
1,034.2/15,502
47% improvement
All studies
47%
0.53 [0.39-0.71]
232/7,454
1,034.2/15,502
47% improvement
10 paxlovid COVID-19 hospitalization results
c19 early.org/pl Feb 2023
Tau2 = 0.16, I2 = 93.5%, p < 0.0001
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW)
19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+
79%
0.21 [0.05-0.82]
death
Arbel 40-64
-32%
1.32 [0.16-10.8]
death
Najjar-Debbiny
46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
death
0/576
1/569
Dryden-Peterson
71%
0.29 [0.12-0.71]
death
Ganatra (PSM)
95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Zhou (PSM)
73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Wong (PSM)
66%
0.34 [0.22-0.52]
death
Schwartz (PSW)
50%
0.50 [0.41-0.61]
death
Bajema (PSM)
58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Zheng (PSW)
-4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Evans
41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Tau2 = 0.07, I2 = 52.9%, p < 0.0001
Early treatment
53%
0.47 [0.38-0.58]
27/13,468
171.6/23,891
53% improvement
All studies
53%
0.47 [0.38-0.58]
27/13,468
171.6/23,891
53% improvement
15 paxlovid COVID-19 serious outcomes
c19 early.org/pl Feb 2023
Tau2 = 0.07, I2 = 52.9%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Zhong
15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Improvement, RR [CI]
Treatment
Control
Pandit
1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Tau2 = 0.00, I2 = 0.0%, p = 0.49
Early treatment
5%
0.95 [0.82-1.10]
0/106
0/36
5% improvement
All studies
5%
0.95 [0.82-1.10]
0/106
0/36
5% improvement
2 paxlovid COVID-19 recovery results
c19 early.org/pl Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.49
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Pfizer (DB RCT)
37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis
37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement
All studies
37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement
1 paxlovid COVID-19 case result
c19 early.org/pl Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.05
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM)
28%
0.72 [0.56-0.93]
viral+
890 (n)
890 (n)
Improvement, RR [CI]
Treatment
Control
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES)
79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu
12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong
16%
0.84 [0.74-0.96]
viral time
106 (n)
36 (n)
Pandit
3%
0.97 [0.83-1.14]
viral+
n/a
n/a
Tau2 = 0.04, I2 = 86.1%, p = 0.00054
Early treatment
25%
0.75 [0.64-0.88]
18/1,205
130/1,378
25% improvement
Li
32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment
32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement
All studies
17%
0.83 [0.77-0.89]
58/1,288
260/1,602
17% improvement
8 paxlovid COVID-19 viral clearance results
c19 early.org/pl Feb 2023
Tau2 = 0.00, I2 = 33.4%, p < 0.0001
1 OT: comparison with other treatment
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
death
0/576
1/569
Tau2 = 0.00, I2 = 0.0%, p = 0.034
Early treatment
90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement
Pfizer (DB RCT)
37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.05
Prophylaxis
37%
0.63 [0.40-1.00]
0/986
0/985
37% improvement
All studies
69%
0.31 [0.06-1.53]
0/2,601
13/2,600
69% improvement
3 paxlovid COVID-19 Randomized Controlled Trials
c19 early.org/pl Feb 2023
Tau2 = 1.01, I2 = 45.5%, p = 0.15
Effect extraction pre-specified (most serious outcome)
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
0/576
1/569
Tau2 = 0.00, I2 = 0.0%, p = 0.034
Early treatment
90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement
All studies
90%
0.10 [0.01-0.84]
0/1,615
13/1,615
90% improvement
2 paxlovid COVID-19 RCT mortality results
c19 early.org/pl Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.034
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Wong (PSM)
66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Yip (PSW)
19%
0.81 [0.47-1.39]
death/ICU
Arbel 65+
79%
0.21 [0.05-0.82]
death
Arbel 40-64
-32%
1.32 [0.16-10.8]
death
Najjar-Debbiny
46%
0.54 [0.39-0.75]
severe case
Dryden-Peterson
71%
0.29 [0.12-0.71]
death
Li (ES)
79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Lu
12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM)
95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong
15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Wong (PSM)
66%
0.34 [0.22-0.52]
death
Tau2 = 0.15, I2 = 86.5%, p < 0.0001
Early treatment
50%
0.50 [0.38-0.66]
18/3,357
152/3,440
50% improvement
Li
32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.0025
Late treatment
32%
0.68 [0.47-0.98]
40/83
130/224
32% improvement
All studies
41%
0.59 [0.48-0.73]
58/3,440
282/3,664
41% improvement
14 paxlovid COVID-19 peer reviewed studies
c19 early.org/pl Feb 2023
Tau2 = 0.08, I2 = 79.5%, p < 0.0001
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors paxlovid
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hammond (DB RCT)
96%
0.04 [0.00-0.68]
death
0/1,039
12/1,046
Improvement, RR [CI]
Treatment
Control
Hammond (DB RCT)
95%
0.05 [0.00-0.89]
death
0/697
9/682
Hammond (DB RCT)
88%
0.12 [0.06-0.26]
hosp.
8/1,039
65/1,046
Hammond (DB RCT)
89%
0.11 [0.04-0.28]
hosp.
5/697
44/682
Wong (PSM)
66%
0.34 [0.23-0.50]
death
890 (n)
890 (n)
Wong (PSM)
3%
0.97 [0.31-3.03]
ventilation
890 (n)
890 (n)
Wong (PSM)
43%
0.57 [0.45-0.72]
progression
890 (n)
890 (n)
Wong (PSM)
4%
0.96 [0.88-1.04]
hosp. time
890 (n)
890 (n)
Wong (PSM)
28%
0.72 [0.56-0.93]
viral+
890 (n)
890 (n)
Yip (PSW)
19%
0.81 [0.47-1.39]
death/ICU
Yip (PSW)
21%
0.79 [0.65-0.95]
hosp.
Arbel 65+
79%
0.21 [0.05-0.82]
death
Arbel 65+
-32%
1.32 [0.16-10.8]
death
Arbel 65+
73%
0.27 [0.15-0.49]
hosp.
Arbel 65+
26%
0.74 [0.35-1.58]
hosp.
Arbel 40-64
-32%
1.32 [0.16-10.8]
death
Arbel 40-64
26%
0.74 [0.35-1.58]
hosp.
Najjar-Debbiny
46%
0.54 [0.39-0.75]
severe case
Pfizer (DB RCT)
67%
0.33 [0.01-8.13]
death
0/576
1/569
Pfizer (DB RCT)
86%
0.14 [0.01-2.75]
ICU
0/576
3/569
Pfizer (DB RCT)
51%
0.49 [0.17-1.44]
death/hosp.
5/576
10/569
Dryden-Peterson
71%
0.29 [0.12-0.71]
death
Dryden-Peterson
44%
0.56 [0.42-0.75]
death/hosp.
Dryden-Peterson
40%
0.60 [0.44-0.81]
hosp.
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Li (ES)
79%
0.21 [0.15-0.28]
viral+
18/175
130/224
Li (ES)
41%
0.59 [0.50-0.69]
viral time
175 (n)
224 (n)
Lu
12%
0.88 [0.78-0.98]
viral+
n/a
n/a
Ganatra (PSM)
95%
0.05 [0.00-0.81]
death
0/1,130
10/1,130
Ganatra (PSM)
39%
0.61 [0.42-0.70]
progression
89/1,130
163/1,130
Ganatra (PSM)
33%
0.67 [0.52-0.87]
progression
89/1,130
163/1,130
Ganatra (PSM)
56%
0.44 [0.21-0.91]
hosp.
10/1,130
23/1,130
Shao
20%
0.80 [0.71-0.91]
viral time
17 (n)
114 (n)
OT1
Zhong
15%
0.85 [0.65-1.13]
recov. time
106 (n)
36 (n)
Zhong
16%
0.84 [0.74-0.96]
viral time
106 (n)
36 (n)
Zhong
16%
0.84 [0.76-0.93]
viral time
106 (n)
36 (n)
Zhou (PSM)
73%
0.27 [0.13-0.58]
death
7/2,808
100/10,849
Zhou (PSM)
75%
0.25 [0.10-0.61]
death
5/2,808
78/10,849
Zhou (PSM)
84%
0.16 [0.11-0.22]
hosp.
34/2,808
752/10,849
Zhou (PSM)
89%
0.11 [0.07-0.17]
hosp.
22/2,808
708/10,849
Wong (PSM)
66%
0.34 [0.22-0.52]
death
Wong (PSM)
38%
0.62 [0.23-1.72]
ventilation
Wong (PSM)
-58%
1.58 [0.95-2.63]
ICU
Wong (PSM)
24%
0.76 [0.67-0.86]
hosp.
Schwartz (PSW)
50%
0.50 [0.41-0.61]
death
Schwartz (PSW)
43%
0.57 [0.48-0.68]
death/hosp.
Pandit
1%
0.99 [0.83-1.17]
no recov.
n/a
n/a
Pandit
3%
0.97 [0.83-1.14]
viral+
n/a
n/a
Pandit
-171%
2.71 [0.86-8.55]
misc.
24/127
3/43
Pandit
-52%
1.52 [0.55-4.25]
misc.
18/127
4/43
Bajema (PSM)
58%
0.42 [0.26-0.67]
death
20/1,587
48.6/1,587
Bajema (PSM)
79%
0.21 [0.08-0.56]
death
5/1,587
23.6/1,587
Bajema (PSM)
48%
0.52 [0.12-2.16]
ventilation
3/1,587
5.8/1,587
Bajema (PSM)
56%
0.44 [0.21-0.92]
ICU
10/1,587
22.8/1,587
Bajema (PSM)
7%
0.93 [0.74-1.16]
hosp.
180/1,587
194.2/1,587
Bajema (PSM)
34%
0.66 [0.45-0.96]
hosp.
43/1,587
65.2/1,587
Zheng (PSW)
-4%
1.04 [0.56-1.93]
death/hosp.
4,836 (n)
2,847 (n)
OT1
Zheng (PSW)
12%
0.88 [0.45-1.71]
death/hosp.
33/4,836
19/2,847
OT1
Evans
41%
0.59 [0.36-0.97]
death/hosp.
602 (n)
4,973 (n)
Li
32%
0.68 [0.47-0.98]
viral+
40/83
130/224
Pfizer (DB RCT)
37%
0.63 [0.40-1.00]
cases
986 (n)
985 (n)
Pfizer (DB RCT)
32%
0.68 [0.46-1.00]
cases
986 (n)
985 (n)
Paxlovid COVID-19 outcomes
c19 early.org/pl Feb 2023
1 OT: comparison with other treatment
Favors paxlovid
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit